Cargando…
Review of withdrawal catatonia: what does this reveal about clozapine?
Withdrawal symptoms are common upon discontinuation of psychiatric medications. Catatonia, a neuropsychiatric condition proposed to be associated with gamma-aminobutyric acid (GABA) hypoactivity due to its robust response to benzodiazepines, has been described as a withdrawal syndrome in case report...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068101/ https://www.ncbi.nlm.nih.gov/pubmed/30065280 http://dx.doi.org/10.1038/s41398-018-0192-9 |
_version_ | 1783343208900591616 |
---|---|
author | Lander, Matthew Bastiampillai, Tarun Sareen, Jitender |
author_facet | Lander, Matthew Bastiampillai, Tarun Sareen, Jitender |
author_sort | Lander, Matthew |
collection | PubMed |
description | Withdrawal symptoms are common upon discontinuation of psychiatric medications. Catatonia, a neuropsychiatric condition proposed to be associated with gamma-aminobutyric acid (GABA) hypoactivity due to its robust response to benzodiazepines, has been described as a withdrawal syndrome in case reports but is not a well-recognized phenomenon. The authors undertook a review of withdrawal catatonia with an aim to understand its presentation as well as the medications and psychoactive substances it is associated with. The review identified 55 cases of withdrawal catatonia, the majority of which occurred upon discontinuation of benzodiazepines (24 cases) and discontinuation of clozapine (20 cases). No other antipsychotic medications were identified as having been associated with the onset of a catatonic episode within 2 weeks following their discontinuation. Increasing GABA activity and resultant GABA receptor adaptations with prolonged use is postulated as a shared pharmacological mechanism between clozapine and benzodiazepines that underlie their association with withdrawal catatonia. The existing evidence for clozapine’s activity on the GABA system is reviewed. The clinical presentations of benzodiazepine withdrawal catatonia and clozapine withdrawal catatonia appear to differ and reasons for this are explored. One reason is that benzodiazepines act directly on GABA(A) receptors as allosteric agonists, while clozapine has more complex and indirect interactions, primarily through effects on receptors located on GABA interneurons. Another possible reason for the difference in clinical presentation is that clozapine withdrawal catatonia may also involve receptor adaptations in non-GABA receptors such as dopamine and acetylcholine. The findings from our review have implications for the treatment of withdrawal catatonia, and treatment recommendations are provided. Further research understanding the uniqueness of clozapine withdrawal catatonia among antipsychotic medication may give some insight as to clozapine’s differential mechanism of action. |
format | Online Article Text |
id | pubmed-6068101 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-60681012018-08-01 Review of withdrawal catatonia: what does this reveal about clozapine? Lander, Matthew Bastiampillai, Tarun Sareen, Jitender Transl Psychiatry Review Article Withdrawal symptoms are common upon discontinuation of psychiatric medications. Catatonia, a neuropsychiatric condition proposed to be associated with gamma-aminobutyric acid (GABA) hypoactivity due to its robust response to benzodiazepines, has been described as a withdrawal syndrome in case reports but is not a well-recognized phenomenon. The authors undertook a review of withdrawal catatonia with an aim to understand its presentation as well as the medications and psychoactive substances it is associated with. The review identified 55 cases of withdrawal catatonia, the majority of which occurred upon discontinuation of benzodiazepines (24 cases) and discontinuation of clozapine (20 cases). No other antipsychotic medications were identified as having been associated with the onset of a catatonic episode within 2 weeks following their discontinuation. Increasing GABA activity and resultant GABA receptor adaptations with prolonged use is postulated as a shared pharmacological mechanism between clozapine and benzodiazepines that underlie their association with withdrawal catatonia. The existing evidence for clozapine’s activity on the GABA system is reviewed. The clinical presentations of benzodiazepine withdrawal catatonia and clozapine withdrawal catatonia appear to differ and reasons for this are explored. One reason is that benzodiazepines act directly on GABA(A) receptors as allosteric agonists, while clozapine has more complex and indirect interactions, primarily through effects on receptors located on GABA interneurons. Another possible reason for the difference in clinical presentation is that clozapine withdrawal catatonia may also involve receptor adaptations in non-GABA receptors such as dopamine and acetylcholine. The findings from our review have implications for the treatment of withdrawal catatonia, and treatment recommendations are provided. Further research understanding the uniqueness of clozapine withdrawal catatonia among antipsychotic medication may give some insight as to clozapine’s differential mechanism of action. Nature Publishing Group UK 2018-07-31 /pmc/articles/PMC6068101/ /pubmed/30065280 http://dx.doi.org/10.1038/s41398-018-0192-9 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Article Lander, Matthew Bastiampillai, Tarun Sareen, Jitender Review of withdrawal catatonia: what does this reveal about clozapine? |
title | Review of withdrawal catatonia: what does this reveal about clozapine? |
title_full | Review of withdrawal catatonia: what does this reveal about clozapine? |
title_fullStr | Review of withdrawal catatonia: what does this reveal about clozapine? |
title_full_unstemmed | Review of withdrawal catatonia: what does this reveal about clozapine? |
title_short | Review of withdrawal catatonia: what does this reveal about clozapine? |
title_sort | review of withdrawal catatonia: what does this reveal about clozapine? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068101/ https://www.ncbi.nlm.nih.gov/pubmed/30065280 http://dx.doi.org/10.1038/s41398-018-0192-9 |
work_keys_str_mv | AT landermatthew reviewofwithdrawalcatatoniawhatdoesthisrevealaboutclozapine AT bastiampillaitarun reviewofwithdrawalcatatoniawhatdoesthisrevealaboutclozapine AT sareenjitender reviewofwithdrawalcatatoniawhatdoesthisrevealaboutclozapine |